You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Toxic Myopathies

Mammen, Andrew L. MD, PhD

CONTINUUM: Lifelong Learning in Neurology:
doi: 10.1212/01.CON.0000440663.26427.f4
Review Articles
Abstract

Purpose: This article reviews the most important muscle toxins, many of which are widely prescribed medications. Particular emphasis is placed on statins, which cause muscle symptoms in a relatively large proportion of the patients who take them.

Recent Findings: As with other toxic myopathies, most cases of statin-associated myotoxicity are self-limited and subside with discontinuation of the offending agent. Importantly, about 2% of the population is homozygous for a single nucleotide polymorphism, and these individuals have a dramatically increased risk of self-limited statin myopathy. Much more rarely, statins trigger a progressive autoimmune myopathy characterized by a necrotizing muscle biopsy and autoantibodies recognizing hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase, the pharmacologic target of statins.

Summary: In most cases, toxic myopathies resolve after the toxic agent is stopped. Recognizing that statins can cause an autoimmune necrotizing myopathy is important because patients with this form of statin-triggered muscle disease usually require immunosuppressive therapy.

Author Information

Address correspondence to Dr Andrew L. Mammen, Johns Hopkins Myositis Center, Johns Hopkins Bayview Medical Center, Mason F. Lord Center Tower, Suite 4500, 5200 Eastern Avenue, Baltimore, MD, 21224, amammen@jhmi.edu.

Relationship Disclosure: Dr Mammen serves on the medical advisory boards of aTyr Pharma and Biogen Idec and has licensed a patent for an anti–HMG-CoA reductase test to INOVA Diagnostics.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Mammen discusses the unlabeled use of therapies for toxic myopathies.

© 2013 American Academy of Neurology